TY - JOUR AU - Szekanecz, Zoltán AU - Szamosi, Szilvia AU - Benkő, Szilvia AU - Szűcs, Gabriella TI - Monogénesen öröklődő és szerzett autoinflammatoricus betegségek JF - ORVOSI HETILAP J2 - ORV HETIL VL - 165 PY - 2024 IS - 18 SP - 683 EP - 697 PG - 15 SN - 0030-6002 UR - https://m2.mtmt.hu/api/publication/34797501 ID - 34797501 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Major, Tamás AU - Nagy, Gábor AU - Szabó, Judit AU - Mózes, Huba AU - Szűcs, Gabriella AU - Szekanecz, Zoltán AU - Szamosi, Szilvia TI - Granulomatosis with polyangiitis or its mimic? A case report JF - JOURNAL OF INTERNATIONAL MEDICAL RESEARCH J2 - J INT MED RES VL - 52 PY - 2024 IS - 4 SP - 1 EP - 8 PG - 8 SN - 0300-0605 DO - 10.1177/03000605241237876 UR - https://m2.mtmt.hu/api/publication/34788385 ID - 34788385 AB - Differentiation between granulomatosis with polyangiitis (GPA) limited to the upper airways and cocaine-induced midline destructive lesion (CIMDL) may be particularly difficult because of their common histopathologic features and antineutrophil cytoplasmic antibody (ANCA) profiles. We herein present a case involving a young woman with an initial diagnosis of GPA based on upper and lower airway manifestations and constitutional symptoms, histopathologic evidence of granulomas, a positive cytoplasmic ANCA indirect immunofluorescent test result, and proteinase 3 positivity by enzyme-linked immunosorbent assay (ELISA). CIMDL was confirmed based on the appearance of a hard palate perforation, positivity for methylecgonine on urine toxicology, a positive perinuclear ANCA indirect immunofluorescent test result, and subsequent human neutrophil elastase (HNE) ANCA positivity by ELISA. Finally, based on the coexistence of CIMDL, constitutional symptoms, and lower airway manifestations, the diagnosis was modified to cocaine-induced GPA mimic. Urine toxicology for cocaine and HNE ELISA are indicated in young patients with GPA who develop limited airway disease to check for the presence of CIMDL and cocaine-/levamisole-induced ANCA-associated vasculitis. Continued abstinence from cocaine is the first-choice therapy for both CIMDL and cocaine-induced GPA mimic. LA - English DB - MTMT ER - TY - JOUR AU - Simon, Diána AU - Kacsándi, Dorottya AU - Karancsiné Pusztai, Anita AU - Soós, Boglárka AU - Végh, Edit AU - Kerekes, György AU - Czókolyová, Monika AU - Szamosi, Szilvia AU - Szűcs, Gabriella AU - Prohászka, Zoltán AU - Németh, Péter AU - Berki, Tímea AU - Szekanecz, Zoltán TI - Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 25 PY - 2024 IS - 6 PG - 14 SN - 1661-6596 DO - 10.3390/ijms25063429 UR - https://m2.mtmt.hu/api/publication/34745209 ID - 34745209 N1 - * Megosztott szerzőség AB - Cardiovascular (CV) morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Natural autoantibodies (nAAb) are involved in innate immunity, as well as autoimmunity, inflammation, and atherosclerosis. There have not been any studies assessing the effects of biologics on nAAbs in RA and AS, also in relation to vascular pathophysiology. Fifty-three anti-TNF-treated RA and AS patients were included in a 12-month follow-up study. Anti-citrate synthase (CS) and anti-topoisomerase I fragment 4 (TOPO-F4) IgM and IgG levels were determined by ELISA. Ultrasonography was performed to assess brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV). Other variables were also evaluated at baseline and 6 and 12 months after treatment initiation. Anti-TNF therapy improved FMD in RA and PWV in AS and stabilized ccIMT. TNF inhibition increased anti-CS IgM and IgG, and possibly also anti-TOPO-F4 IgG levels. Various correlation analyses revealed that nAAbs might be independently involved in autoimmunity as well as changes in inflammation and vascular pathology over time in biologic-treated patients (p < 0.05). We also found associations between anti-TOPO-F4 IgG and anti-Hsp60 IgG (p < 0.05). Baseline nAAb levels or nAAb level changes might determine changes in CRP, disease activity, FMD, PWV, and ccIMT over time (p < 0.05). The interplay between arthritis and inflammatory atherosclerosis, as well as the effects of anti-TNF biologics on these pathologies, might independently involve nAAbs. LA - English DB - MTMT ER - TY - JOUR AU - Charles‐Schoeman, Christina AU - Fleischmann, Roy AU - Mysler, Eduardo AU - Greenwald, Maria AU - Ytterberg, Steven R. AU - Koch, Gary G. AU - Bhatt, Deepak L. AU - Wang, Cunshan AU - Mikuls, Ted R. AU - Chen, All‐shine AU - Connell, Carol A. AU - Woolcott, John C. AU - Menon, Sujatha AU - Chen, Yan AU - Lee, Kristen AU - Szekanecz, Zoltán TI - Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐enriched Rheumatoid Arthritis Patients JF - ARTHRITIS & RHEUMATOLOGY J2 - ARTHRITIS RHEUMATOL PY - 2024 SN - 2326-5191 DO - 10.1002/art.42846 UR - https://m2.mtmt.hu/api/publication/34742893 ID - 34742893 LA - English DB - MTMT ER - TY - JOUR AU - Zimmerman, Daniel H. AU - Szekanecz, Zoltán AU - Markovics, Adrienn AU - Rosenthal, Kenneth S. AU - Carambula, Roy E. AU - Mikecz, Katalin TI - Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 15 PY - 2024 SP - 1 EP - 13 PG - 13 SN - 1664-3224 DO - 10.3389/fimmu.2024.1334281 UR - https://m2.mtmt.hu/api/publication/34724777 ID - 34724777 AB - Rheumatoid arthritis (RA) is recognized as an autoimmune joint disease driven by T cell responses to self (or modified self or microbial mimic) antigens that trigger and aggravate the inflammatory condition. Newer treatments of RA employ monoclonal antibodies or recombinant receptors against cytokines or immune cell receptors as well as small-molecule Janus kinase (JAK) inhibitors to systemically ablate the cytokine or cellular responses that fuel inflammation. Unlike these treatments, a therapeutic vaccine, such as CEL-4000, helps balance adaptive immune homeostasis by promoting antigen-specific regulatory rather than inflammatory responses, and hence modulates the immunopathological course of RA. In this review, we discuss the current and proposed therapeutic products for RA, with an emphasis on antigen-specific therapeutic vaccine approaches to the treatment of the disease. As an example, we describe published results of the beneficial effects of CEL-4000 vaccine on animal models of RA. We also make a recommendation for the design of appropriate clinical studies for these newest therapeutic approaches, using the CEL-4000 vaccine as an example. Unlike vaccines that create or boost a new immune response, the clinical success of an immunomodulatory therapeutic vaccine for RA lies in its ability to redirect autoreactive pro-inflammatory memory T cells towards rebalancing the “runaway” immune/inflammatory responses that characterize the disease. Human trials of such a therapy will require alternative approaches in clinical trial design and implementation for determining safety, toxicity, and efficacy. These approaches include adaptive design (such as the Bayesian optimal design (BOIN), currently employed in oncological clinical studies), and the use of disease-related biomarkers as indicators of treatment success. LA - English DB - MTMT ER - TY - CHAP AU - Bodnár, Nóra AU - Szekanecz, Zoltán ED - Bereczky, Zsuzsanna ED - Bagoly, Zsuzsa ED - Katona, Éva TI - A klinikai vizsgálatok monitorozása, a szponzor, CRO és vizsgálóhelyek viszonya, a "Case report form" T2 - Klinikai kutatások - átfogó ismeretek a tervezéstől a közlésig PB - Medicina Könyvkiadó Zrt. CY - Budapest SN - 9789632269115 PY - 2024 SP - 101 EP - 109 PG - 9 UR - https://m2.mtmt.hu/api/publication/34560656 ID - 34560656 LA - Hungarian DB - MTMT ER - TY - CHAP AU - Szekanecz, Zoltán AU - Bodnár, Nóra ED - Bereczky, Zsuzsanna ED - Bagoly, Zsuzsa ED - Katona, Éva TI - A GCP elemei, a helyes klinikai gyakorlat irányelvei T2 - Klinikai kutatások - átfogó ismeretek a tervezéstől a közlésig PB - Medicina Könyvkiadó Zrt. CY - Budapest SN - 9789632269115 PY - 2024 SP - 93 EP - 100 PG - 8 UR - https://m2.mtmt.hu/api/publication/34560646 ID - 34560646 LA - Hungarian DB - MTMT ER - TY - CHAP AU - Szekanecz, Zoltán AU - Bodnár, Nóra ED - Bereczky, Zsuzsanna ED - Bagoly, Zsuzsa ED - Katona, Éva TI - Az intervenciós klinikai vizsgálatok tervezésének, kivitelezésének sajátosságai; a klinikai gyógyszervizsgálatok típusai; kockázatok T2 - Klinikai kutatások - átfogó ismeretek a tervezéstől a közlésig PB - Medicina Könyvkiadó Zrt. CY - Budapest SN - 9789632269115 PY - 2024 SP - 85 EP - 92 PG - 8 UR - https://m2.mtmt.hu/api/publication/34560632 ID - 34560632 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Tar, Ildikó AU - Végh, Edit AU - Martos, Renáta AU - Boglárka, Soós AU - Márton, Ildikó AU - Szekanecz, Zoltán TI - Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 13 PY - 2024 PG - 10 SN - 2077-0383 DO - 10.3390/jcm13020448 UR - https://m2.mtmt.hu/api/publication/34502100 ID - 34502100 LA - English DB - MTMT ER - TY - JOUR AU - Szekanecz, Zoltán AU - Buch, Maya H. AU - Charles-Schoeman, Christina AU - Galloway, James AU - Karpouzas, George A. AU - Kristensen, Lars Erik AU - Ytterberg, Steven R. AU - Hamar, Attila AU - Fleischmann, Roy TI - Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician JF - NATURE REVIEWS RHEUMATOLOGY J2 - NAT REV RHEUMATOL PY - 2024 SN - 1759-4790 DO - 10.1038/s41584-023-01062-9 UR - https://m2.mtmt.hu/api/publication/34502024 ID - 34502024 LA - English DB - MTMT ER -